loading page

AllergoOncology: Is ultra-low IgE a potential novel biomarker in cancer? A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)
  • +20
  • Denisa Ferastraoaru,
  • Heather Bax,
  • Bergmann Christoph,
  • Monique Capron,
  • Mariana Castells,
  • David Dombrowicz,
  • Edda Fiebiger,
  • Hannah Gould,
  • Karin Hartmann,
  • Uta Jappe,
  • Galateja Jordakieva,
  • Debra Josephs,
  • Francesca Levi-Schaffer,
  • Vera Mahler,
  • Aurelie Poli,
  • David Rosenstreich,
  • Franziska Roth-Walter,
  • Mohammed Shamji,
  • Esther Steveling,
  • Michelle Turner,
  • Eva Untersmayr,
  • Sophia Karagiannis,
  • Erika Jensen-Jarolim
Denisa Ferastraoaru
Montefiore Medical Center
Author Profile
Heather Bax
King's College London
Author Profile
Bergmann Christoph
ENT Research Institute for Clinical Studies
Author Profile
Monique Capron
Inserm U995
Author Profile
Mariana Castells
Brigham and Women's Hospital
Author Profile
David Dombrowicz
U1011 - récepteurs nucléaires, maladies cardiovasculaires et diabète
Author Profile
Edda Fiebiger
Children's Hospital Boston
Author Profile
Hannah Gould
Randall Centre for Cell and Molecular Biophysics,
Author Profile
Karin Hartmann
University of Basel
Author Profile
Uta Jappe
Research Centre Borstel
Author Profile
Galateja Jordakieva
Medizinische Universitat Wien
Author Profile
Debra Josephs
King's College London
Author Profile
Francesca Levi-Schaffer
The Hebrew University of Jerusalem
Author Profile
Vera Mahler
Paul-Ehrlich-Institut
Author Profile
Aurelie Poli
Luxembourg Institute of Health
Author Profile
David Rosenstreich
Montefiore Medical Center
Author Profile
Franziska Roth-Walter
Messerli Research Institute
Author Profile
Mohammed Shamji
Imperial College London
Author Profile
Esther Steveling
University Hospital Basel
Author Profile
Michelle Turner
Instituto de Salud Global Barcelona
Author Profile
Eva Untersmayr
Center of Physiology, Pathophysiology and Immunology
Author Profile
Sophia Karagiannis
King’s College London
Author Profile
Erika Jensen-Jarolim
Messerli Research Institute
Author Profile

Abstract

Elevated serum IgE levels are associated with allergic disorders, parasitosis and specific immunologic abnormalities. In addition, epidemiological and mechanistic evidence indicates an association between IgE-mediated immune surveillance and protection from tumour growth. Intriguingly, recent studies reveal a correlation between IgE deficiency and increased malignancy risk. This is the first review focusing on IgE levels and links to pathological conditions, with special focus on the potential clinical significance of ultra-low serum IgE levels and risk of malignancy. In this Position Paper we discuss: a) the utility of measuring total IgE levels in the management of allergies, parasitosis, and immunodeficiencies, b) factors that may influence serum IgE levels, c) IgE as a marker of different disorders, and d) the relationship between ultra-low IgE levels and malignancy susceptibility. While elevated serum IgE is generally associated with allergic/atopic conditions, very low or absent IgE may hamper anti-tumour surveillance, indicating the importance of a balanced IgE-mediated immune function. Ultra-low IgE may prove to be an unexpected biomarker for cancer risk. Nevertheless, given the early stage of investigations conducted mostly in cohort of patients with diseases that influence IgE levels, in-depth mechanistic studies and stratification of malignancy risk based on associated demographic, immunological and clinical co-factors are warranted.

Peer review status:Published

Dec 2020Published in Clinical and Translational Allergy volume 10 issue 1. 10.1186/s13601-020-00335-w